Both in Biotechnology
Exelixis vs Neurocrine Biosciences
Over the past year EXEL returned +44.6% and NBIX returned −1.4%; their daily moves had a correlation of 0.44.
EXEL +44.6% NBIX −1.4%Growth of $1, one year, split-adjusted
| Metric | EXEL | NBIX |
|---|---|---|
| Price | $58.65 | $138.35 |
| Market cap | $14.53B | $14.06B |
| Today | +0.48% | −1.49% |
| 1 month | +7.7% | −10.2% |
| 6 months | +39.8% | +7.5% |
| Year to date | +33.8% | −2.5% |
| 1 year | +50.2% | −2.6% |
| Revenue growth (YoY) | +10.6% | +39.5% |
| Gross margin | 96.7% | 97.6% |
| Net margin | 33.7% | 15.1% |
| P/E (TTM) | 16.9× | 19.9× |
| Price / sales | 6.0× | 4.2× |
| Net cash | $839.4M | $389.8M |
| Dividend yield | — | — |
| Volatility (60d) | 34.5% | 34.4% |
| Short % of float | 10.8% | 5.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).